前列腺癌
医学
聚ADP核糖聚合酶
PARP抑制剂
合成致死
癌症研究
同源重组
DNA修复
癌症
DNA损伤修复
前列腺
内科学
肿瘤科
聚合酶
DNA
生物
遗传学
作者
Arshit Narang,Chadi Hage Chehade,Zeynep İrem Özay,Blake Nordblad,Umang Swami,Neeraj Agarwal
标识
DOI：10.1080/14656566.2024.2397002
摘要
Introduction Around 25% of patients with advanced prostate cancer harbor alterations in the homologous recombination/DNA damage repair (HRR) pathway. Inhibiting poly (ADP-ribose) polymerase (PARP) in these patients leads to synthetic lethality, making PARP inhibitors (PARPi), including talazoparib, a promising treatment for metastatic castration-resistant prostate cancer (mCRPC) and potentially for metastatic hormone-sensitive prostate cancer (mHSPC).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
GingerF
辛勤的诗柳
唐泽雪穗
彩虹儿
大气的幻天
GIINJIU
YifanWang
tuanheqi
dongjingbutaire
pearson
carols
光亮的代云
路人甲
Rita
刘厚麟
GPTea
Thien
環宸
小花排草
科目三
浮浮世世
JW
打工小房
CodeCraft
whoKnows
CAP
lgq12697
ldkl
皖公网安备34019202002308
